title: New antibiotics for healthcare-associated pneumonia.
abstract: Current antibiotics available for the treatment of healthcare-associated pneumonia (HCAP) may result in clinical failure due to resistance development, side effect intolerance, or poor pharmacokinetic-pharmacodynamic profiles. New agents active against common HCAP pathogens are needed. The mechanism of action, spectrum of activity, pharmacokinetics, adverse effects, and clinical efficacy of seven new agents in clinical development or recently approved with either methicillin-resistant Staphylococcus aureus (MRSA) or pseudomonal activity are reviewed. They include doripenem, a new antipseudomonal carbapenem; ceftobiprole and ceftaroline, two anti-MRSA cephalosporins; iclaprim, a selective dihydrofolate reductase antagonist; and three glycopeptides, dalbavancin, telavancin, and oritavancin.
authors.affiliation: Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri 63110, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Neuner
authors.forename: David J
authors.initials: DJ
authors.lastname: Ritchie
authors.forename: Scott T
authors.initials: ST
authors.lastname: Micek
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015780:Carbapenems / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D000077726:Doripenem; D006020:Glycopeptides / Q000627:therapeutic use; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000097583:Ceftaroline; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; D000077726:Doripenem; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D011743:Pyrimidines; D017334:Teicoplanin; D000097583:Ceftaroline; C486448:iclaprim; C443755:ceftobiprole; C469289:dalbavancin; C100708:oritavancin; D014640:Vancomycin; C487637:telavancin